Fondaparinux Sodium

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

B01AX05

CAS registry number (Chemical Abstracts Service)

0114870-03-0

Chemical Formula

C31-H43-N3-Na10-O49-S8

Molecular Weight

1728

Therapeutic Category

Anticoagulant agent: Selective inhibitor of blood-coagulation factor Xa

Chemical Name

Methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-ß-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-OR-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyrano (WHO)

Foreign Names

• Fondaparinuxum natricum (Latin)
• Fondaparinux natrium (German)
• Fondaparinux sodique (French)
• Fondaparinux sodico (Spanish)

Generic Names

• Fondaparinux Sodium (OS: BAN, USAN)
• Fondaparin sodium (IS)
• Fondaparinux (IS)
• IC 851589 (IS)
• Org 35140 (IS: Organon)
• Pentasaccharid Faktor Xa-Inhibitor (IS: selektiv)
• SR 90107A (IS: SanofiSynthela)
• Xantidar (IS)

Brand Names

• Arixtra
  Glaxo Group, Austria; Glaxo Group, Iceland; Glaxo Group, Luxembourg; Glaxo SmithKline, Spain; GlaxoSmithKline, Antigua & Barbuda; GlaxoSmithKline, Netherlands Antilles; GlaxoSmithKline, Australia; GlaxoSmithKline, Aruba; GlaxoSmithKline, Barbados; GlaxoSmithKline, Belgium; GlaxoSmithKline, Bermuda; GlaxoSmithKline, Bahamas; GlaxoSmithKline, Canada; GlaxoSmithKline, Switzerland; GlaxoSmithKline, China; GlaxoSmithKline, Colombia; GlaxoSmithKline, Costa Rica; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Dominican Republic; GlaxoSmithKline, Finland; GlaxoSmithKline, France; GlaxoSmithKline, United Kingdom; GlaxoSmithKline, Grenada; GlaxoSmithKline, Guatemala; GlaxoSmithKline, Guyana; GlaxoSmithKline, Honduras; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Hungary; GlaxoSmithKline, Indonesia; GlaxoSmithKline, Italy; GlaxoSmithKline, Jamaica; GlaxoSmithKline, Cayman Islands; GlaxoSmithKline, Saint Lucia; GlaxoSmithKline, Mexico; GlaxoSmithKline, Malaysia; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Norway; GlaxoSmithKline, Panama; GlaxoSmithKline, Peru; GlaxoSmithKline, Portugal; GlaxoSmithKline, Russian Federation; GlaxoSmithKline, Sweden; GlaxoSmithKline, Singapore; GlaxoSmithKline, Slovenia; GlaxoSmithKline, Slovakia; GlaxoSmithKline, El Salvador; GlaxoSmithKline, Thailand; GlaxoSmithKline, Turkey; GlaxoSmithKline, Trinidad & Tobago; GlaxoSmithKline, United States; GlaxoSmithKline, South Africa; Sanofi-aventis, Greece; Sanofi-aventis, Oman



• Quixidar
  GlaxoSmithKline, Slovakia

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.